We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Bortezomib disrupts tumour--dendritic cell interactions in myeloma and lymphoma: therapeutic implications.
- Authors
Kukreja, Anjli; Hutchinson, Aisha; Mazumder, Amitabha; Vesole, David; Angitapalli, Revathi; Jagannath, Sundar; O'Connor, Owen A.; Dhodapkar, Madhav V.
- Abstract
Recent studies have shown that the interactions between tumour and dendritic cells (DCs) promote clonogenic growth of lymphoproliferative tumours, particularly myeloma. The present study showed that the proteasome inhibitor, bortezomib, disrupts this interaction. Targeting the drug to DCs was required for optimal suppression of tumour growth, including primary myeloma tumour progenitors in clonogenic assays. Bortezomib lead to dose-dependent induction of apoptosis in both myeloid and plasmacytoid DCs, and the sensitivity of DCs to bortezomib was comparable with that of tumour cells. These data suggest that disruption of tumour-DC interactions may contribute to the clinical effects of bortezomib.
- Subjects
TUMOR treatment; CANCER treatment; LYMPHOMAS; DENDRITIC cells; CELL death; LYMPHOPROLIFERATIVE disorders
- Publication
British Journal of Haematology, 2007, Vol 136, Issue 1, p106
- ISSN
0007-1048
- Publication type
Article
- DOI
10.1111/j.1365-2141.2006.06369.x